SMNR · Semnur Pharmaceuticals, Inc. · Executive Compensation
$0.45
+0.00 (+0.00%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$137.90M
Shares
230.21M
Volume · Oct 5
6104
Avg daily vol (3M)
9954
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Stephen Ma | Chief Operating Officer | Appointed | 2026-03-17 |
| Henry Ji | Chief Executive Officer and President | Appointed | 2026-03-17 |
| Jaisim Shah | director | Resigned | 2026-03-17 |
| Jaisim Shah | Chief Executive Officer and President | Retired | 2026-03-17 |
| Stephen Ma | Chief Financial Officer, Senior Vice President and Secretary | Appointed | 2025-09-26 |
| Jaisim Shah | Chief Executive Officer and President | Appointed | 2025-09-26 |
| Henry Ji, Ph.D. | Executive Chairperson | Appointed | 2025-09-26 |
| Yue Alexander Wu, Ph.D. | Class II director | Appointed | 2025-09-26 |
| Jaisim Shah | Class III director | Appointed | 2025-09-26 |
| Henry Ji, Ph.D. | Class III director | Appointed | 2025-09-26 |
| Annu Navani, M.D. | Class I director | Appointed | 2025-09-26 |
| Dorman Followwill | Class II director | Appointed | 2025-09-26 |
| Jay Chun, M.D., Ph.D. | Class I director | Appointed | 2025-09-26 |